{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:17:37Z","timestamp":1775193457576,"version":"3.50.1"},"reference-count":17,"publisher":"Walter de Gruyter GmbH","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2020-0848_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Due to its high specificity, liquid chromatography-tandem mass spectrometry (LC-MS\/MS) is considered the gold standard in diagnostic areas such as therapeutic monitoring of immunosuppressive drugs (ISDs). However, many laboratories still rely on immunoassays for ISD quantification in a tradeoff between analytical performance and the advantages of fully automated analyzers\u00a0\u2013 shorter turnaround times, greater ease of use, and 24\/7 availability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2020-0848_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The LC-MS\/MS-based Thermo Scientific\u2122 Cascadion\u2122 SM Immunosuppressant Panel was evaluated for &gt;6\u00a0months in the routine laboratory of a university hospital. We assessed the analytical performance of the panel and compared it to conventional LC-MS\/MS as well as to immunoassays (cyclosporine A, sirolimus, tacrolimus (Siemens) and everolimus (Thermo Fisher)). In addition, both ISD panel and Cascadion analyzer were scrutinized with regards to, e.g., turnaround time, usability, and robustness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2020-0848_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All ISDs showed high linearity and precision (CV\u22646%) and a good correlation with conventional LC-MS\/MS. The mean deviation to the immunoassays was 17\u201319% and negative for all ISDs except everolimus with a positive 19% bias. No weak points were revealed when challenging assay and system with, e.g., high haematocrit, sedimented whole blood or priority samples. The Cascadion integrated well into our 24\/7 routine and could easily be operated simultaneously with several other analyzers by technical staff without LC-MS experience.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2020-0848_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The ISD panel showed excellent analytical performance and demonstrated that a fully automated LC-MS-based analysis starting from primary samples is feasible, suggesting that LC-MS could become an integral part of 24\/7 diagnostics in the near future.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2020-0848","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T05:33:34Z","timestamp":1603517614000},"page":"913-920","source":"Crossref","is-referenced-by-count":29,"title":["Evaluation of the first immunosuppressive drug assay available on a fully automated LC-MS\/MS-based clinical analyzer suggests a new era in laboratory medicine"],"prefix":"10.1515","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5718-1530","authenticated-orcid":false,"given":"Sebastian","family":"H\u00f6rber","sequence":"first","affiliation":[{"name":"Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich, University of T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Peter","sequence":"additional","affiliation":[{"name":"Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich, University of T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"German Center for Diabetes Research (DZD) , M\u00fcnchen-Neuherberg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich, University of T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"German Center for Diabetes Research (DZD) , M\u00fcnchen-Neuherberg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7014-1501","authenticated-orcid":false,"given":"Miriam","family":"Hoene","sequence":"additional","affiliation":[{"name":"Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich, University of T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"2023033113430132688_j_cclm-2020-0848_ref_001","doi-asserted-by":"crossref","unstructured":"Seger, C, Salzmann, L. After another decade: LC-MS\/MS became routine in clinical diagnostics. Clin Biochem 2020;82:2\u201311. https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.03.004.","DOI":"10.1016\/j.clinbiochem.2020.03.004"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_002","doi-asserted-by":"crossref","unstructured":"Heaney, LM. Advancements in mass spectrometry as a tool for clinical analysis: part II. Clin Chem Lab Med 2020;58:855\u20137. https:\/\/doi.org\/10.1515\/cclm-2020-0259.","DOI":"10.1515\/cclm-2020-0259"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_003","doi-asserted-by":"crossref","unstructured":"Gounden, V, Soldin, SJ. Tacrolimus measurement: building a better immunoassay. Clin Chem 2014;60:575\u20136. https:\/\/doi.org\/10.1373\/clinchem.2013.220012.","DOI":"10.1373\/clinchem.2013.220012"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_004","doi-asserted-by":"crossref","unstructured":"McShane, AJ, Bunch, DR, Wang, S. Therapeutic drug monitoring of immunosuppressants by liquid chromatography-mass spectrometry. Clin Chim Acta 2016;454:1\u20135. https:\/\/doi.org\/10.1016\/j.cca.2015.12.027.","DOI":"10.1016\/j.cca.2015.12.027"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_005","doi-asserted-by":"crossref","unstructured":"Wallemacq, PE. Therapeutic monitoring of immunosuppressant drugs. Where are we? Clin Chem Lab Med 2004;42:1204\u201311. https:\/\/doi.org\/10.1515\/cclm.2004.242.","DOI":"10.1515\/CCLM.2004.242"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_006","doi-asserted-by":"crossref","unstructured":"Zhang, Y, Zhang, R. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs. Drug Test Anal 2018;10:81\u201394. https:\/\/doi.org\/10.1002\/dta.2290.","DOI":"10.1002\/dta.2290"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_007","doi-asserted-by":"crossref","unstructured":"Qin, X, Rui, J, Xia, Y, Mu, H, Song, SH, Raja Aziddin, RE, Miles, G, et al. Multi-center performance evaluations of tacrolimus and cyclosporine electrochemiluminescence immunoassays in the Asia-Pacific region. Ann Lab Med 2018;38:85\u201394. https:\/\/doi.org\/10.3343\/alm.2018.38.2.85.","DOI":"10.3343\/alm.2018.38.2.85"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_008","doi-asserted-by":"crossref","unstructured":"Taguchi, K, Ohmura, T, Ohya, Y, Horio, M, Furukawa, K, Jono, H, et al. False tacrolimus concentrations measured by antibody-conjugated magnetic immunoassay in liver transplant patient: 2 case reports and literature review. Exp Clin Transplant 2014;12:474\u20138. https:\/\/doi.org\/10.6002\/ect.2013.0113.","DOI":"10.6002\/ect.2013.0113"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_009","doi-asserted-by":"crossref","unstructured":"Morelle, J, Wallemacq, P, Van Caeneghem, O, Goffin, E. Clinically unexpected cyclosporine levels using the ACMIA method on the RXL dimension analyser. Nephrol Dial Transplant 2011;26:1428\u201331. https:\/\/doi.org\/10.1093\/ndt\/gfr002.","DOI":"10.1093\/ndt\/gfr002"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_010","doi-asserted-by":"crossref","unstructured":"Peter, A, Shipkova, M, Wieland, E, Schleicher, E, M\u00fcller, I. Increased cyclosporine concentrations in the absence of cyclosporine administration. Clin Chem 2011;57:670\u20133. https:\/\/doi.org\/10.1373\/clinchem.2010.148718.","DOI":"10.1373\/clinchem.2010.148718"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_011","doi-asserted-by":"crossref","unstructured":"Schniedewind, B, Niederlechner, S, Galinkin, J, Johnson-Davis, K, Christians, U, Meyer, E. Long-term cross-validation of everolimus therapeutic drug monitoring assays: the Zortracker study. Ther Drug Monit 2015;37:296\u2013303. https:\/\/doi.org\/10.1097\/ftd.0000000000000191.","DOI":"10.1097\/FTD.0000000000000191"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_012","doi-asserted-by":"crossref","unstructured":"Christians, U, Vinks, AA, Langman, LJ, Clarke, W, Wallemacq, P, van Gelder, T, et al. Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs. Ther Drug Monit 2015;37:718\u201324. https:\/\/doi.org\/10.1097\/FTD.0000000000000205.","DOI":"10.1097\/FTD.0000000000000205"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_013","doi-asserted-by":"crossref","unstructured":"Benton, SC, Tetteh, GK, Needham, S-J, M\u00fccke, J, Sheppard, L, Alderson, S, et al. Evaluation of the 25-hydroxy vitamin D assay on a fully automated liquid chromatography mass spectrometry system, the thermo scientific cascadion SM clinical analyzer with the cascadion 25-hydroxy vitamin D assay in a routine clinical laboratory. Clin Chem Lab Med 2020;58:1010\u20137. https:\/\/doi.org\/10.1515\/cclm-2019-0834.","DOI":"10.1515\/cclm-2019-0834"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_014","doi-asserted-by":"crossref","unstructured":"Shipkova, M, Rapp, S, Rigo-Bonnin, R, Wieland, E, Peter, A. Therapeutic drug monitoring of everolimus: comparability of concentrations determined by 2 immunoassays and a liquid chromatography tandem mass spectrometry method. Ther Drug Monit 2017;39:102\u20138. https:\/\/doi.org\/10.1097\/ftd.0000000000000376.","DOI":"10.1097\/FTD.0000000000000376"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_015","doi-asserted-by":"crossref","unstructured":"Salvagno, GL, Danese, E, Lippi, G. Mass spectrometry and total laboratory automation: opportunities and drawbacks. Clin Chem Lab Med 2020;58:994\u20131001. https:\/\/doi.org\/10.1515\/cclm-2019-0723.","DOI":"10.1515\/cclm-2019-0723"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_016","doi-asserted-by":"crossref","unstructured":"Jannetto, PJ, Fitzgerald, RL. Effective use of mass spectrometry in the clinical laboratory. Clin Chem 2016;62:92\u20138. https:\/\/doi.org\/10.1373\/clinchem.2015.248146.","DOI":"10.1373\/clinchem.2015.248146"},{"key":"2023033113430132688_j_cclm-2020-0848_ref_017","doi-asserted-by":"crossref","unstructured":"Vogeser, M. From therapeutic drug monitoring to total drug monitoring and drug-omics. Clin Chem Lab Med 2020;59:287\u201390. https:\/\/doi.org\/10.1515\/cclm-2020-0339.","DOI":"10.1515\/cclm-2020-0339"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/cclm\/ahead-of-print\/article-10.1515-cclm-2020-0848\/article-10.1515-cclm-2020-0848.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-0848\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-0848\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T19:09:45Z","timestamp":1680289785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-0848\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":17,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,12,4]]},"published-print":{"date-parts":[[2021,4,27]]}},"alternative-id":["10.1515\/cclm-2020-0848"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2020-0848","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]}}}